The blood-brain barrier remains one of drug development's toughest obstacles — it excludes nearly all large biologics and most small molecules, leaving current CNS delivery approaches far from ideal. As a result, researchers are increasingly exploring smarter strategies to get therapeutics across, including exploiting the barrier's own natural transport mechanisms.
In this short video, Isogenica — The VHH Company — sets out the scale of the BBB challenge and why natural transport routes are gaining attention as a more targeted way through.
Watch the full video here: https://www.youtube.com/watch?v=R60td4g0two
